00:41 , Feb 9, 2018 |  BC Innovations  |  Product R&D

R is for readout

While AstraZeneca plc gets credit for transparency in publishing its metrics on R&D productivity, the data cover well-established targets addressed by conventional modalities. The more telling test for its “5R framework” will be whether it...
16:29 , Feb 7, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Polyamine-based nanoparticles loaded with AGO2 could be used as delivery vehicles for therapeutic siRNA. The nanoparticles consist of a polyamine capsule containing a therapeutic siRNA and AGO2, an RNA-induced silencing complex (RISC)-interacting protein that...
07:00 , May 12, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-551b (miR-551b); signal transducer and activator of transcription 3 (STAT3)

Cancer INDICATION: Ovarian cancer Patient sample, cell culture and mouse studies suggest inhibiting miR-551b or STAT3 could help treat serous ovarian cancer. In patients with high-grade serous ovarian cancer, miR-551b levels were higher in ovarian tumor samples...
07:00 , Aug 10, 2015 |  BioCentury  |  Strategy

Isis executes

Isis Pharmaceuticals Inc. has planted a second pillar in its strategy of pursuing expansive long-term relationships that combine its antisense capabilities with the scientific and clinical expertise of its partners. On Aug. 3, the...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Isis Pharmaceuticals, AstraZeneca deal

Isis received a $7.5 million milestone payment from AstraZeneca under a December 2012 deal to discover antisense therapeutics against four undisclosed cancer targets from AZ. The payment was triggered by the advancement of ISIS-STAT3Rx,...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Company News

Isis Pharmaceuticals, AstraZeneca deal

The companies partnered to develop new targeted delivery methods for antisense oligonucleotides with a focus on cancer and cardiovascular and metabolic diseases. Each company will provide funding and investigators and share rights to the results....
02:23 , Nov 14, 2014 |  BC Extra  |  Top Story

AstraZeneca, Isis team up on antisense delivery

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Isis Pharmaceuticals Inc. (NASDAQ:ISIS) partnered to develop new targeted delivery methods for antisense oligonucleotides with a focus on cancer and cardiovascular and metabolic diseases. Each company will provide investigators and...
07:00 , Jul 17, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer CTLA-4 (CD152); signal transducer and activator of transcription 3 (STAT3) In vitro and mouse studies suggest...
07:00 , Jul 10, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer; melanoma Signal transducer and activator of transcription 3 (STAT3) In vitro and mouse studies suggest compounds...
07:00 , Jun 9, 2014 |  BioCentury  |  Emerging Company Profile

Glactone: ProSTATe stopper

Glactone Pharma AB is developing small molecule inhibitors of a mitogenic transcription factor that is overactive in castration-resistant prostate cancer and other solid tumors. The company has mechanistic evidence that its derivatives of the fungal...